Protalix BioTherapeutics (PLX) Cash from Investing Activities (2010 - 2026)

Protalix BioTherapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 1453.53% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 51.96% YoY), while the FY2025 annual figure was -$2.4 million, down 156.05% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $4.2 million, up from -$1.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $20.3 million in Q3 2024, with the low at -$20.9 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is -$312000.0 (2025), against an average of -$921647.1.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities sank 4379.53% in 2024, then soared 1453.53% in 2026.
• Protalix BioTherapeutics' Cash from Investing Activities stood at $5.0 million in 2022, then plunged by 106.9% to -$342000.0 in 2023, then tumbled by 4379.53% to -$15.3 million in 2024, then surged by 92.74% to -$1.1 million in 2025, then surged by 479.77% to $4.2 million in 2026.
• Business Quant data shows PLX's Cash from Investing Activities at $4.2 million in Q1 2026, -$1.1 million in Q4 2025, and -$504000.0 in Q3 2025.